ATNM — Actinium Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $31.06m
- -$11.06m
- $0.09m
Brief: Actinium Presents Data From Phase 3 SIERRA Trial
Brief: Actinium Pharmaceuticals Inc To Highlight IOMAB-B Pivotal Phase 3 Sierra Trial Data At The Transplantation & Cellular Therapy Tandem Meetings Of Astct And Cibmtr
U.S. RESEARCH ROUNDUP-Edwards Lifesciences, Intuitive Surgical, Thor Industries
Actinium jumps on commercialization deal with Sweden's Immedica for cancer therapy
Brief: Actinium Pharmaceuticals, Immedica Announce Commercialization Agreement For Iomab-B
Brief: Actinium Pharmaceuticals Presents Preclinical Data Related To Her3 Targeted Radiotherapy
Brief: Actinium Pharmaceuticals Highlights Potent Anti-Tumor Activity Of A Her3 Targeted Radiotherapy At AACR
U.S. RESEARCH ROUNDUP- Astec Industries, ChampionX, Schlumberger NV
Brief: Actinium Pharmaceuticals And Aveo Oncology Enter Research Collaboration Agreement
Brief: Actinium Pharmaceuticals, Inc. And EpicentRx Announce Strategic Research Collaboration To Combine Targeted Radiotherapies With Next Generation Cd47/Sirpα Immunotherapy
Brief: Actinium Pharmaceuticals Inc Reports 2 Remissions And 67% ORR In Patients With A Tp53 Mutation In The Phase 1 Portion Of The Actimab-A Venetoclax Combination Trial In Patients With Relapsed Or Refractory Aml At The 63Rd Ash Annual Meeting
Brief: Actinium Pharma Reports 72% MRD Negativity Rate in Phase 1 Study of Actimab-A in Relapsed or Refractory AML
Brief: Actinium Says Difference Of 5X For Iomab-B Vs Control Arm In The Number Of Patients Potentially Evaluable For Primary Endpoint Of Phase 3 Sierra Trial
Brief: Actinium Presents Data Of Solid Tumors Treatment At SITC Conference
Brief: Actinium Announces Completion of Enrollment Of Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia Fit for Induction Therapy
Brief: Actinium Announces Multiple Senior Leadership Appointments
U.S. RESEARCH ROUNDUP:-Cisco, GXO Logistics, Theravance Biopharma
Actinium climbs on completing patient enrollment in cancer therapy study
Brief: Actinium Completes Enrollment In The Pivotal Phase 3 Sierra Trial Of Iomab-B